



## HIV Pathogenesis, Vaccine and Eradication Strategies

Guest Editor:

**Dr. Mudit Tyagi**

Department of Medicine, Thomas  
Jefferson University,  
Philadelphia, PA 19107, USA

Deadline for manuscript  
submissions:

**closed (28 February 2022)**

### Message from the Guest Editor

Dear Colleagues,

Human Immunodeficiency Virus (HIV) is still a very big problem for humanity. Fortunately, current anti-HIV drug regimens are highly effective in controlling HIV transmission and replication. Notably, it has been well established that current anti-HIV therapy would not be able to eradicate or cure HIV. Numerous strategies have been applied unsuccessfully to flush out the latent HIV reservoirs, the main hurdle in HIV eradication. However, due to mutadaptability of HIV, both preventive and therapeutic vaccines have been proved ineffective. In addition, several other prophylactic approaches, including microbicides, are struggling to make impact.

We are interested in a broader area of research, focusing primarily on the mechanisms of HIV pathogenesis, life cycle, latency and therapeutics. In addition, we are calling manuscripts dealing with vaccine trials (pre-clinical and clinical) and strategies to develop more effective HIV vaccine. We are looking forward to have a combination of manuscripts that deals with different vital aspects of HIV, which could be exploited to develop more effective anti-HIV therapy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)